Objective:

To summarize key clinical updates on kidney cancer presented at GU ASCO 2025.

Key Findings:

• Cabozantinib plus Nivolumab (Cabo-Nivo) shows improved PFS but no OS benefit compared to Sunitinib in favorable risk patients.
• COSMIC313 trial indicates no OS benefit for triplet therapy (Cabo-Nivo-Ipi) compared to Ipi-Nivo, highlighting the need for further research.
• M2 macrophage levels may predict benefit from triplet therapy, suggesting a potential biomarker for patient selection.

Interpretation:

While novel therapies show promise in improving PFS, the lack of OS benefits raises questions about their long-term efficacy, particularly in favorable risk patients, necessitating further investigation.

Limitations:

• High rates of grade 3-4 adverse events, including liver toxicities, with triplet therapy may limit its use.
• Need for further investigation into biomarkers, such as M2 macrophages, to identify patients who may benefit from aggressive treatment.

Conclusion:

Current findings suggest a need for improved treatment strategies in kidney cancer, particularly for patients with aggressive disease, while addressing the limitations of current therapies.